Page 104 - 中国药房2023年10期

lecularly targeted therapy and the use of tumor biomarkers （2）：228-247.
in the treatment of metastatic colorectal cancer[J]. Cancer， [17] FREITES-MARTINEZ A，SANTANA N，ARIAS-SANTIAGO
2019，125（23）：4139-4147. S，et al. Using the common terminology criteria for
[ 5 ] OVERMAN M J，ERNSTOFF M S，MORSE M A. Where adverse events （CTCAE-version 5.0） to evaluate the
we stand with immunotherapy in colorectal cancer： severity of adverse events of anticancer therapies[J]. Actas
deficient mismatch repair，proficient mismatch repair，and Dermosifiliogr （Engl Ed），2021，112（1）：90-92.
toxicity management[J]. Am Soc Clin Oncol Educ Book， [18] SIEGEL R，DESANTIS C，JEMAL A. Colorectal cancer
2018，38：239-247. statistics，2014[J]. CA Cancer J Clin，2014，64（2）：
[ 6 ] LIMAGNE E，THIBAUDIN M，NUTTIN L，et al. Trifluri‐ 104-117.
dine/tipiracil plus oxaliplatin improves PD-1 blockade in [19] GANESH K，STADLER Z K，CERCEK A，et al. Immuno‐
colorectal cancer by inducing immunogenic cell death and therapy in colorectal cancer：rationale，challenges and po‐
depleting macrophages[J]. Cancer Immunol Res，2019，7 tential[J]. Nat Rev Gastroenterol Hepatol，2019，16（6）：
（12）：1958-1969. 361-375.
[ 7 ] WANG Y Y，WEI B，GAO J H，et al. Combination of fru‐ [20] LE D T，URAM J N，WANG H，et al. PD-1 blockade in tu‐
quintinib and anti-PD-1 for the treatment of colorectal can‐ mors with mismatch-repair deficiency[J]. N Engl J Med，
cer[J]. J Immunol，2020，205（10）：2905-2915. 2015，372（26）：2509-2520.
[ 8 ] AKIN TELLI T，BREGNI G，VANHOOREN M，et al. [21] GAUDREAU P O，NEGRAO M V，MITCHELL K G，et
Regorafenib in combination with immune checkpoint in‐ al. Neoadjuvant chemotherapy increases cytotoxic T cell，
hibitors for mismatch repair proficient（pMMR）/microsa- tissue resident memory T cell，and B cell infiltration in re‐
tellite stable（MSS）colorectal cancer[J]. Cancer Treat sectable NSCLC[J]. J Thorac Oncol，2021，16（1）：
Rev，2022，110：102460. 127-139.
[ 9 ] KODAMA H，TERAZAWA T，ISHIZUKA Y，et al. Retro‐ [22] LUPO G，CAPORARELLO N，OLIVIERI M，et al. Anti-
spective comparison of mFOLFOXIRI with XELOX/SOX angiogenic therapy in cancer：downsides and new pivots
as neoadjuvant chemotherapy for locally advanced rectal for precision medicine[J]. Front Pharmacol，2016，7：519.
cancer[J]. In Vivo，2021，35（2）：977-985. [23] FUKUMURA D，KLOEPPER J，AMOOZGAR Z，et al.
[10] GOU H F，ZHOU L，HUANG J，et al. Intraperitoneal oxa- Enhancing cancer immunotherapy using antiangiogenics：
liplatin administration inhibits the tumor immunosuppres‐ opportunities and challenges[J]. Nat Rev Clin Oncol，
sive microenvironment in an abdominal implantation 2018，15（5）：325-340.
model of colon cancer[J]. Mol Med Rep，2018，18（2）： [24] LI R R，YIN X L，ZENG D Y，et al. Efficacy and safety of
2335-2341. anti-PD-1 antibody plus regorafenib in refractory micro‐
[11] LI N，ZHU Y，LIU L Y，et al. Postoperative chemoradio‐ satellite stable metastatic colorectal cancer：a retrospective
therapy with capecitabine and oxaliplatin vs capecitabine single-arm cohort study[J]. Ann Transl Med，2022，10
for stage Ⅱ to Ⅲ rectal cancer：a randomized clinical trial （16）：880.
[J]. JAMA Netw Open，2021，4（11）：e2136116. [25] QIN S K，LI Q，GU S Z，et al. Apatinib as second-line or
[12] JAVLE M M，OH D Y，IKEDA M，et al. Varlitinib plus later therapy in patients with advanced hepatocellular car‐
capecitabine in second-line advanced biliary tract cancer： cinoma （AHELP） ：a multicentre，double-blind，ran‐
a randomized，phase Ⅱ study（TreeTopp）[J]. ESMO domised，placebo-controlled，phase 3 trial[J]. Lancet Gas‐
Open，2022，7（1）：100314. troenterol Hepatol，2021，6（7）：559-568.
[13] LI A Y，WANG K，XU A G，et al. Apatinib as an optional [26] WANG F，QIN S K，SUN X C，et al. Reactive cutaneous
treatment in metastatic colorectal cancer[J]. Medicine capillary endothelial proliferation in advanced hepatocel-
（Baltimore），2019，98（35）：e16919. lular carcinoma patients treated with camrelizumab：data
[14] MARKHAM A，KEAM S J. Camrelizumab：first global derived from a multicenter phase 2 trial[J]. J Hematol On‐
approval[J]. Drugs，2019，79（12）：1355-1361. col，2020，13（1）：47.
[15] ZHOU H，WANG Y H，LIN Y F，et al. Preliminary effi‐ [27] CHEN L，JIANG Y Z，WU S Y，et al. Famitinib with cam‐
cacy and safety of camrelizumab in combination with relizumab and nab-paclitaxel for advanced immunomodu‐
XELOX plus bevacizumab or regorafenib in patients with latory triple-negative breast cancer（FUTURE-C-plus）：an
metastatic colorectal cancer：a retrospective study[J]. open-label，single-arm，phase Ⅱ trial[J]. Clin Cancer Res，
Front Oncol，2021，11：774445. 2022，28（13）：2807-2817.
[16] EISENHAUER E A，THERASSE P，BOGAERTS J，et al. （收稿日期：2022-09-20 修回日期：2023-03-20）
New response evaluation criteria in solid tumours：revised （编辑：张元媛）
RECIST guideline：version 1.1[J]. Eur J Cancer，2009，45

· 1246 · China Pharmacy 2023 Vol. 34 No. 10 中国药房 2023年第34卷第10期